An experimental ALS drug being developed in New Haven will be tested next year in a first-of-its-kind clinical trial led by Massachusetts General Hospital.
Biohaven Pharmaceuticals’ verdiperstat was one of five drugs selected from a pool of roughly 30 potential new treatments for amyotrophic lateral sclerosis, the deadly neurodegenerative condition also known as Lou Gehrig’s Disease. more